glp 1 receptor agonist agent GLP-1 agonists show promise in treating substance use disorders GLP-1: Genetic Variants Related to

Eli Lilly and Novo Nordisk are closing in on deals with the Trump administration that would exchange deep discounts on their weight loss drugs for coverage under Medicare, per Endpoints News

Gastrointestinal symptoms such as nausea, constipation, and indigestion are most common and usually subside as your body adjusts

The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157

| 10 comments on LinkedIn

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.